Navigation Links
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
Date:11/2/2009

BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1. In the lead-in arms of the study, in which patients received a 4-week lead-in of PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) followed by the addition of narlaprevir, 85-87 percent of patients achieved rapid virologic response (RVR), compared to 58-75 percent of patients in the no lead-in narlaprevir arms and no patients in the PEGINTRON and REBETOL control arm. RVR, defined in this study as undetectable virus (HCV RNA) at week 4 of narlaprevir treatment, is recognized as an important predictor for achieving sustained virologic response. These interim results from the NEXT-1 study were reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.[1]

"These interim results, while preliminary, are very encouraging, and showed that narlaprevir has potent antiviral activity in hepatitis C," said John Vierling, M.D., professor of medicine and surgery, chief of hepatology, Baylor College of Medicine, Houston, and the lead investigator of the study. "In this study, once-daily narlaprevir greatly improved viral clearance at week 4 of treatment in genotype 1 hepatitis C infection compared to the control group. We look forward to further results from this ongoing study."

Importantly, patients in the lead-in narlaprevir arms also achieved improved rates of early virologic response (EVR), defined as undetectable virus at week 12 of treatment, with 85-87 percent of patients having undetectable
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) today announced ... Firm of the Year by the Tech Council of ... TCM,s 25 th Annual Tech Awards Celebration held in ... recognizes the leaders and innovators in the technology and life ... surrounding regions. "We are deeply honored to ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... Annual  Healthcare Conference on Thursday, May 30, 2013, at ... beginning at 9:20 a.m. Eastern Daylight Time. Arvind ... will present at the conference. Live audio of the presentation ... www.amgen.com , under Investors. A replay of the webcast ...
(Date:5/23/2013)... May 23, 2013 Hearing health affects a man,s ... and remain socially and professionally engaged, he should address any ... message that the Better Hearing Institute (BHI) is ... National Men,s Health Week , which leads up to and ... from June 10 through June 16. To ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4
(Date:5/24/2013)... With today’s levels of weight gain and obesity ... the causes of weight gain and how to lose weight ... of weight gain and treatments that will help patients lose ... by the Child Study Center at NYU Langone Medical Center ... ADHD and the soring rates of obesity later in life. ...
(Date:5/24/2013)... May 24, 2013 Today marks the ... online Itinerary Builder. , The redesigned and enhanced ... unique vacation itineraries on their computer or mobile device ... The interactive tool allows users to fill in their ... through and select their choice of vacation packages, accommodations, ...
(Date:5/24/2013)... CA (PRWEB) May 24, 2013 ... today of the latest update involving allegations that ... Zmax SR (azithromycin) can allegedly cause potentially ... Company reported on May 17, 2013* that Health ... Administration in warning that Zithromax can cause abnormal ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Scott Ryan ... brother, Troy Tischler, lose 200 lbs. of fat in ... Tischler teach his younger brother the importance of exercising. ... diet. By sticking to these 7 rules of healthy ... loss goals can be accomplished. , 1.    Find a distraction ...
(Date:5/24/2013)... Psoriasis treatment cream has been released online for ... registered company is now offering its natural solution to ... infected skin. , Dermasis has launched its new psoriasis ... cream is designed to offer immediate relief to those ... red skin often caused by psoriasis outbreaks. This new ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Now Help Patients with Weight Gain Linked to Childhood ADHD Lose Weight Fast 2Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 2Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 3Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 4Health News:Dermasis Psoriasis Treatment Cream for Men and Women Released Online at HealthCareSupplementz.com 2
... , WASHINGTON, July 22 The ... in the new book, Rethinking Responsibility: Reflections on Sex ... Teen and Unplanned Pregnancy, a nonprofit, nonpartisan organization, the volume includes ... , , , ...
... NEW YORK and SAN FRANCISCO, July 22 WeissComm ... Weiss , who was recently named an "Emerging Power Player" by ... the inaugural CLIO Healthcare Awards . The awards honor creative ... , About the CLIO Healthcare Awards and Entry ...
... HOUSTON, July 22 Service Corporation International (NYSE: SCI ) ... the second quarter 2009 on Wednesday, August 5, 2009, after the market ... Thursday, August 6, 2009. Details of the conference call are as ... Service Corporation International Second Quarter 2009 Earnings Conference Call , ...
... Proteus syndrome is a complex disorder associated with ... and unregulated adipose tissue. The overgrowth seen in ... Patients with Proteus syndrome require repeated treatment for ... period. Aggressive treatment may cause severe functional and ...
... , BINGHAM FARMS, Mich., July 22 ... as the new Director of Strategic Partnerships. Terrisca comes to ... Lives Save Dollars (SLSD) initiative where she served most recently as ... with key regional, state, national and international organizations to advance the ...
... , , , ... Board: ACCP) announced today that Jeffrey B. Davis, President & CEO, ... the LifeTech Capital Group on Thursday, July 30, 2009 at 10:45 am EDT. ... Astoria Boca Beach Club in Boca Raton, Florida. , , ...
Cached Medicine News:Health News:National Leaders Examine Sex and Responsibility in New Book 2Health News:National Leaders Examine Sex and Responsibility in New Book 3Health News:WeissComm Group CEO Jim Weiss Appointed Founding Board Member and Judge of First-Ever CLIO Healthcare Awards 2Health News:WeissComm Group CEO Jim Weiss Appointed Founding Board Member and Judge of First-Ever CLIO Healthcare Awards 3Health News:Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call 2Health News:Terrisca Des Jardins, MHSA, joins my1HIE as Director of Strategic Partnerships 2Health News:Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference 2
Microporous tape sheets for covering 96-well plates, square-well or flat-bottom blocks.;...
ThermalSeal RT (2mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates....
Sealing tape, slightly stiffer than Polyolefin tape....
Sealing tape featuring 3M adhesive technology. Compatible with DMSO. Good optical quality. Minimal autofluorescence....
Medicine Products: